Work

Emerging Frontiers in the Treatment of Non-small Cell Lung Cancer: Innovations and Clinical Advances

Year: 2025

Type: article

Abstract: Clinical Question BoxWhat are the current strategies for selecting optimal treatment regimens for patients with nonsmall cell lung cancer (NSCLC)?Treatment selection for NSCLC is guided by molecular profiling, PD-L1 expression, tumor histology, and patient factors.Targeted therapies are preferred for tumors with actionable mutations like EGFR, ALK, ROS1, BRAF, MET, RET, KRAS G12C, HER2, or NTRK.If no mutations are found, PD-L1 levels guide therapy: ≥50% often leads to immunotherapy alone, while lower levels usually require chemo-immunotherapy.Chemotherapy choices depend on histology, with pemetrexed used for non-squamous tumors and taxanes or gemcitabine for squamous types.Patient fitness, comorbidities, and emerging biomarkers, such as circulating tumor DNA, further personalize treatment.

Source: Journal of Clinical Question

DOI: 10.69854/jcq.2025.0024

Authors: Yang An, Cong Zu, Xiaotong Zhuang, Xinyu Zheng, Yoshiko Yasuda, Miao Tang